Skip to main content

Table 3 Clinical characteristics of 12 CAEBV patients

From: Chronic active Epstein-Barr virus infection involving gastrointestinal tract mimicking inflammatory bowel disease

NO Sex Age ranges Course of disease Symptoms EBV-DNA (copies/ml) Surgery Medicine Prognosis
1 1 20–30 3 years Fever, hematochezia 4.34*10^6 NO Steroids, antibiotics and antiviral-drugs Dead
2 1 50–60 3 months Fever, vomiting, diarrhea NA NO Steroids, antibiotics and thalidomide Dead
3 1 40–50 4 months Fever, hematochezia NA NO Steroids, antiviral-drugs and immunoglobulin Dead
4 1 40–50 3 years Fever, vomiting, diarrhea 4.0*10^7 NO Steroids and immunoglobulin Dead
5 1 30–40 2 months Fever, hematochezia 1.14*10^7 NO Steroids and antivirus Dead
6 1 40–50 2 years Fever, hematochezia 1.22*10^5 YES Steroids Dead
7 1 20–30 1 year Fever, diarrhea 1.54*10^6 NO Steroids Dead
8 2 30–40 3 years Fever, vomiting, abdominal pain, diarrhea 3.12*10^5 NO Steroids, antiviral-drugs and immunoglobulin Dead
9 1 40–50 17 months Fever, abdominal pain 1.09*10^3 YES Steroids, antiviral-drugs Dead
10 1 40–50 2 months Fever, abdominal pain, hematochezia 1.29*10^6 NO Steroids Survive
11 1 50–60 1 month Fever, abdominal pain, diarrhea 1.85*10^4 NO Steroids and hemopoietic stem cell transplantation Survive
12 1 70–80 3 months Fever, diarrhea, hematochezia 1.63*10^6 NO Steroids and antibiotics Dead
  1. In consideration for patients’anonymity, we amend sex from “male” and “female” to “1” and “2”for publication